Welcome to LookChem.com Sign In|Join Free
  • or
methyl (2S,5S,8S)-2-allyl-8-(4-allyloxybenzyl)-3,6,9-triaza-5-(3-[N'-{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-chromen-6-ylsulfonyl}guanidino]propyl)-4,7,10-trioxoundecanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

900522-08-9

Post Buying Request

900522-08-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

900522-08-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 900522-08-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,0,5,2 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 900522-08:
(8*9)+(7*0)+(6*0)+(5*5)+(4*2)+(3*2)+(2*0)+(1*8)=119
119 % 10 = 9
So 900522-08-9 is a valid CAS Registry Number.

900522-08-9Relevant academic research and scientific papers

New cyclic peptides via ring-closing metathesis reactions and their anti-bacterial activities

Boyle, Timothy P.,Bremner, John B.,Coates, Jonathan,Deadman, John,Keller, Paul A.,Pyne, Stephen G.,Rhodes, David I.

experimental part, p. 11270 - 11290 (2009/04/06)

As part of a program investigating cyclic peptides with an internal aromatic hydrophobic scaffold as potential novel anti-bacterial agents, we explored the synthesis of simple tyrosine-based systems. These were prepared via key intermediates containing internal allylglycine and allyltyrosine residues for subsequent ring-closing metathesis reactions. Although the resulting anti-bacterial activity against Staphylococcus aureus was modest, this represents a novel and simple route to this class of compounds. One intermediate acyclic dipeptide precursor showed good activity against S. aureus with an MIC of 7.8 μg/mL. Crown Copyright

PEPTIDIC COMPOUNDS

-

Page/Page column 146, (2008/06/13)

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 900522-08-9